Provided by Tiger Trade Technology Pte. Ltd.

SBP GROUP

5.480
-0.130-2.32%
Volume:79.10M
Turnover:436.47M
Market Cap:102.38B
PE:36.13
High:5.640
Open:5.520
Low:5.475
Close:5.610
52wk High:8.901
52wk Low:4.136
Shares:18.68B
HK Float Shares:18.68B
Volume Ratio:0.81
T/O Rate:0.42%
Dividend:0.12
Dividend Rate:2.19%
EPS(LYR):0.152
ROE:14.07%
ROA:7.51%
PB:2.69
PE(LYR):36.13
PS:2.60

Loading ...

China Biopharmaceuticals (01177) Mid-Year Review: Betting Big on AI and Global Expansion as Twin Growth Engines

Stock News
·
Aug 19

SBP Group H1 2026 Results: Revenue Climbs 10.6%, Innovative Drug Sales Surge 44.3%

Bulletin Express
·
Aug 19

Sino Biopharmaceutical Sets HKD 0.07 Interim Dividend, Payable 24 September 2026

Bulletin Express
·
Aug 19

Sino Biopharmaceutical H1 Revenue up 10.6% on Innovative Drug Sales

Reuters
·
Aug 19

SBP Group Profit Attributable to Owners Rises 1.4% to RMB 3.43 Billion in 1H FY26; Revenue Climbs 10.6% to RMB 19.44 Billion

Reuters
·
Aug 19

Sino Biopharm Declares 2026 Interim Dividend of HKD 0.07 a Share

Reuters
·
Aug 19

Sino Biopharmaceutical H1 Revenue RMB 1,944 Million

THOMSON REUTERS
·
Aug 19

Sino Biopharmaceutical - Interim Dividend of Hk7 CENTS\nPER Share

THOMSON REUTERS
·
Aug 19

Ping an Healthcare Names Yougang Zhu Chairman in Board Reshuffle

Reuters
·
Aug 18

Sino Biopharmaceutical Stock Falls 2.0% in Hong Kong, Underperforms Competitors

Dow Jones
·
Aug 14

Sino Biopharmaceutical Stock Sheds 1.5% in Hong Kong, Underperforms Competitors

Dow Jones
·
Aug 12

Earning Preview: SBP GROUP Q2 revenue is expected to increase, and institutional views are cautiously positive

Earnings Agent
·
Aug 12

Sino Biopharmaceutical Stock Sheds 0.9% in Hong Kong, Underperforms Competitors

Dow Jones
·
Aug 10

Movement Alert|SBP GROUP Rises 3.83% in Regular Trading, Beimosubai Plus Anlotinib Lung Squamous Cell Carcinoma Indication Approved

Market Focus
·
Aug 10

SK Hynix Greenlights 54 Trillion Won Chip Expansion; Beijing Slashes Homebuying Tax Threshold for Non-Local Families to One Year

Stock News
·
Aug 10

Sino Biopharmaceutical Says NMPA Approves Benmelstobart

Reuters
·
Aug 08

Sino Biopharma Unit Gets China Nod to Market Lung Cancer Drug

MT Newswires Live
·
Aug 07

SBP Group Receives Approval for New Lung Cancer Treatment Combination

Stock News
·
Aug 07

Sino Biopharma Wins China NMPA Approval for First-Line Squamous NSCLC Combo Therapy

Reuters
·
Aug 07

Sino Biopharmaceutical - Nmpa Approves Benmelstobart with Chemotherapy Followed by Anlotinib for First-Line Sq-Nsclc

THOMSON REUTERS
·
Aug 07